[252 Pages Report] The single-cell analysis market is projected to reach $5.6 billion by 2025 from $2.1 billion in 2019, at a CAGR of 17.8% during the forecast period.
The study involved four major activities in estimating the current size of the single cell analysis market. Exhaustive secondary research was conducted to collect information on the market as well as its peer and parent markets. The next step is to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both the top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the sizes of segments and sub-segments.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254
The growth in this market is driven by technological advancements in single-cell analysis products, increasing government funding for cell-based research, growing biotechnology and bio-pharmaceutical industries, wide applications of single-cell analysis in cancer research, growing focus on personalized medicine, and the increasing incidence and prevalence of chronic and infectious diseases.
Which is the leading product type of single-cell analysis?
Based on the product type, the global single-cell analysis market is segmented broadly into instruments and consumables. In 2018, consumables commanded the largest share of single-cell analysis market. The large share of this segment can primarily be attributed to the frequent purchase of these products as compared to instruments, which are considered as a one-time investment, and their wide applications in research and genetic exploration, exosome analysis, and isolation of RNA and DNA.
Which is the leading application for single-cell analysis instruments and consumables?
Based on technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques. The flow cytometry segment accounted for the largest market share in 2018. The large share of this segment is attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles. However, the NGS segment is projected to register the highest growth rate during the forecast period. The high growth of the NGS segment is driven by the increasing application of single-cell analysis products in drug discovery for cancer and other chronic diseases.
Recent Developments in the Worldwide Industry:
- In November 2019, QIAGEN launched QIAseq Multimodal Panels, which have been developed for consolidated targeted DNA and RNA enrichment and analyses. These panels save time and conserve samples that are of limited availability.
- In July 2019, QIAGEN partnered with Illumina with the aim to broaden the availability and use of NGS-based in vitro diagnostic (IVD) kits.
- In June 2019, Beckman Coulter acquired Cytobank, Inc. (US) to integrate Cytobank’s software into Beckman Coulter’s product portfolio to provide innovative solutions to customers.
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171955254
Which geographical region is dominating in the single-cell analysis market?
The single-cell analysis market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East and Africa. In 2018, North America dominated the single-cell analysis market, followed by Europe. However, the Asia Pacific market is estimated to register the highest CAGR during the forecast period. The growth in this market can be attributed to the increasing drug development activities in the pharmaceutical and biotechnology industries, rising prevalence of chronic and infectious diseases, and an increase in stem cell research activities.
Key Market Players:
Prominent players in the single-cell analysis market are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).